OBJECTIVE -The aim of the study was to assess the prevalence of cutaneous disorders and their relation to disease duration, metabolic control, and microvascular complications in children and adolescents with type 1 diabetes.
T
hough it is well known that diabetes is associated with a number of cutaneous manifestations (1) (2) (3) , there is a relative paucity of studies looking at the prevalence of skin changes in young patients with type 1 diabetes. Cutaneous manifestations generally appear subsequent to the development of diabetes but may be the first presenting sign or even precede the diagnosis by many years. The cutaneous findings can be classified into four major groups: 1) skin diseases associated with diabetes, such as scleroderma-like changes of the hand, necrobiosis lipoidica, and diabetic dermopathy; 2) cutaneous infections; 3) cutaneous manifestations of diabetes complications, such as neuropathic foot ulcers; and 4) skin reactions to diabetes treatment (1) .
To understand the development of skin lesions and their relationship to diabetes complications, a useful approach would be a long-term follow-up of type 1 diabetic patients and/or surveys of cutaneous disorders in younger type 1 diabetic subjects. Available data suggest that skin dryness and scleroderma-like changes of the hand represent the most common cutaneous manifestations of type 1 diabetes seen in up to 49% of the patients (3). They are interrelated and also related to diabetes duration. Timing of appearance of various cutaneous lesions in young patients with diabetes might be potentially useful for the research of their pathogenesis (i.e., derangement of epidermal lipid metabolism), therapeutic intervention (i.e., application of moisturizers or antifibrosing agents), or predicting microvascular complications. We decided to examine an unselected young type 1 diabetic population to see what kind of cutaneous manifestations develop at an earlier age and with a shorter duration of diabetes.
RESEARCH DESIGN AND METHODS -Two hundred and twelve children, adolescents, and young adults with type 1 diabetes (113 male and 99 female subjects), with disease onset at age Յ15 years (Table 1) and consecutively attending the outpatient diabetes clinic at the Mother and Child Healthcare Institute of Serbia over a 5-month period (April through August 2005), were examined by two dermatologists. They took a medical history about skin diseases and performed the whole-body cutaneous examination, including visible mucosal surfaces. During the same time frame, 196 healthy children and adolescents (115 male and 81 female subjects, aged 3-21 years, mean 11.5 Ϯ 4.2) attending the dental medicine service of the Military Medical Academy for a routine dental check-up also underwent dermatological examination by the same physicians. All clinically definable cutaneous lesions were recorded in both populations. Scleroderma-like skin changes of the
hand were diagnosed and assessed according to the criteria of Seibod (4). Xerosis (acquired ichthyosis) was clinically diagnosed based on the palpatory feeling of dry and rough skin accompanied by visible squames. The disorder was typically most severe over shins. In a few cases in which the diagnoses of the two examiners were discordant, they examined the patient together with a third dermatologist and reached a consensus. Medical files were reviewed for data on diabetes duration, A1C levels, fasting triglycerides, cholesterol and thyroidstimulating hormone levels, and renal function. Cumulative A1C values as a measure of glucose control were expressed as a mean of the yearly A1C levels. Retinopathy was diagnosed by an experienced ophthalmologist using direct and indirect ophthalomoscopy, nephropathy was assessed by means of albumin excretion rate using three consecutive timed overnight urine collections (albumin excretion rate Ն20 g/min in at least two of three measurements), and peripheral neuropathy was assessed by means of a positive diabetic neuropathy index (5) and, when indicated, electromyoneurography.
Statistical analysis
Statistical tests were performed using SPSS 8.0 for Windows (StatSoft). The 2 test was used to assess differences between the prevalence of cutaneous lesions in patients and control subjects ( Table 2) . P values were based on a two-sided test and considered significant if Ͻ0.01.
Stepwise logistic regression was used to assess significant associations of cutaneous lesions with clinical and metabolic parameters of the patients with type 1 diabetes.
Due to a well-known ␣-inflation associated with stepwise logistic regression and several regressions performed, a cutoff for significance level for variables in the model was set at P Յ 0.01.
RESULTS -
The clinical data of the study population are given in Table 1 . A total of 142 patients (68%) had at least one cutaneous disorder, and 81 patients (38%) had skin lesions considered to be associated with diabetes ( Table 2 ). The most prevalent cutanous manifestation was xerosis, found in 22% of type 1 diabetic patients. In control subjects, the ichthyosiform changes affected only 3% of the children and adolescents. The difference was highly significant (Table 2 ; P Ͻ 0.01). Thyroid-stimulating hormone levels were normal in all patients with ichthyosiform skin changes. Rubeosis, diabetic hand (scleroderma-like changes and/or limited joint mobility), and necrobiosis lipoidica were found only in patients with type 1 diabetes ( Table 2 ). All five subjects with diabetic hand were boys, and two of them also had Dupuytren's contracture. The prevalence of necrobiosis lipoidica in our type 1 diabetic population was 2.3%. Though the prevalence of fungal, viral, and bacterial infections was higher in the study population (4.3, 4.3, and 3.0%, respectively) than in control subjects, the difference Data are means Ϯ SD (range) or n (%). was not significant and the numbers were generally low. Keratosis pilaris, though not considered a diabetes-related cutaneous manifestation, was significantly more common (11.7%) in type 1 diabetic patients than in control subjects (1.5%) (P Ͻ 0.01). The prevalence of acne was comparable in both populations (Table  2 ). Other cutaneous disorders were uncommon and listed in Table 2 .
Stepwise logistic regression was used to assess the influence of diabetes risk factors and late complications (disease duration, metabolic control, and nephropathy) on skin lesions. We found that diabetic hand was significantly related to the disease duration (odds ratio 1.42 [95% CI 1.11-1.81]; P Ͻ 0.001) with no evidence to relate it to either metabolic control or nephropathy. Rubeosis faciei was less strongly related to the disease duration (1.22 [1.04 -1.43]; P ϭ 0.0087). Ichthyosiform skin changes were significantly related only to keratosis pilaris (1.53 [1.09 -1.79]; P Ͻ 0.001). There was no association of the mean values of triglycerides, fasting cholesterol, thyroid-stimulating hormone levels, or blood pressure with any of the cutaneous disorders.
CONCLUSIONS -This study was performed within a young population of type 1 diabetic patients. Disease duration and age of patients were lower than in two similar cross-sectional studies (4 vs. 10 and 13 years and 12 vs. 22 and 23 years, respectively). This is certainly a reason for the low prevalence of cutaneous disorders associated with diabetes. The exception is xerosis, found in 22% of patients vs. 3% of control subjects. In the series of Romano et al. (2) , only 6% of their patients had xerosis. Yosipovitch et al. (3) registered 48% of the patients with ichthyosiform shin changes in their series of patients. Despite possible definition discrepancies across the studies, it is clear that the skin dryness is one of the earliest and most common manifestations of type 1 diabetes. The clinical observations are supported by objective findings of a reduced hydration state of the stratum corneum and decreased sebaceous gland activity in patients with diabetes, without any impairment of the stratum corneum barrier function (6) . Even in the absence of clinically apparent xerosis, patients with diabetes have an impaired desquamation process (7) . Similarly to a previous series of young patients with type 1 diabetes (3), ichthyosiform lesions in our patients were not associated with known causes of acquired ichthyosis (e.g., atopic dermatitis), nutritional deficiencies, or chronic renal failure.
The prevalence of rubeosis faciei in our patients with type 1 diabetes was rather high (7%) and was twice as much as in a similar previous study (3), and it was found to be weakly (P ϭ 0.0087) related to the disease duration. The prevalence in most previous studies in patients with type 2 diabetes was estimated at 21-59% (8, 9) . It is presumed that venular dilation in the cheeks of diabetic patients underlies rubeosis faciei and is caused by hyperglycemia-induced sluggish microcirculation (10) . Hypertension may exacerbate the capillary damage (10) . We could not demonstrate any relation of rubeosis faciei in our young patients with type 1 diabetes with metabolic control, and only one patient had concomitant hypertension. It is interesting that in the Italian series (2) of 64 patients with type 1 diabetes, rubeosis faciei was not seen in any of the patients.
Diabetic hand, a variety of sclerodermoid lesions in diabetic patients, was seen in only 2.3% of our patients but was strongly related to diabetes duration (P Ͻ 0.001). In young patients with type 1 diabetes with a three-times-longer disease duration, the prevalence of sclerodermalike changes of the hand was 39% (3). All of our five patients with diabetic hand were boys aged Ͼ14 years with mean diabetes duration of 9 years. Previous studies (10) have shown a correlation of these changes with the duration of diabetes and increasing age. The association with microvascular complications could not be assessed, as they were extremely rare in our young patient population. It seems that scleroiderma-like lesions of the hand are a late complication of type 1 diabetes, at least if compared with ichthyosiform skin changes. Advanced glycosylation is believed to underlie the connective tissue changes in this disorder (3, 11) .
We found necrobiosis lipoidica in 2.3% (n ϭ 5) of our patients with type 1 diabetes (mean age 14 years, mean disease duration 7 years; four girls), but no significant relationship to disease duration, age, or metabolic control was confirmed. Studies (8, (12) (13) (14) indicated the prevalence of 0.3-1.2% among diabetic patients, and two-thirds of them had type 1 diabetes. In young subjects with type 1 diabetes, necrobiosis lipoidica was found in 1.6% of the patients (3). We cannot account for the higher prevalence of necrobiosis lipoidica in our population of type 1 diabetic patients, and although microangiopathy has been proposed as a causative factor for necrobiosis (10) , none of our patients had retinopathy or nephropathy.
The prevalence of cutaneous infections, though somewhat higher in the population of type 1 diabetic patients, was not statistically different from the healthy subjects (Table 2) . Dermatophyte infections (tinea pedis and onychomycosis) were diagnosed in 2.8% and candidosis in 1.9% of our diabetic patients. The figures are very close to those found among 64 type 1 diabetic patients in the study of Romano et al. (2) , where the prevalence of tinea infections was 3% and of Candida infections 5%. The figures were higher for their type 2 diabetic patients (ϳ20%). Two larger studies in nonselected adult diabetic patients demonstrated mycologically proven dermatophyte infections in 4 and 31% of patients, respectively, but the prevalence was similar or higher in control subjects (15, 16) . However, Yosipovitch et al. (3) reported tinea pedis in 36% of their young type 1 diabetic patients versus only 7% in control subjects. On balance, contrary to a common belief, it seems that dermatophyte and canidida infections are not more common in patients with diabetes in general as compared with healthy individuals.
Cutaneous reactions to insulin therapy (lipoatrophy and lipohypertrophy) were observed in only six patients in our series (four with lipohypertrophy [1.8%] ). In the largest study of skin disorders in young type 1 diabetic patients, these changes were seen in 6.5% of patients (3). The prevalence of lipohypertrophy in type 1 diabetic patients in two studies specifically looking at the disorder was very high (29 and 48%) (17, 18) . de Villiers (19) , in his 33 young patients with type 1 diabetes, using careful palpation, not only visible lesions, found the prevalence of 52% and even 80% when only patients examined on several occasions were counted. On the other hand, Romano et al. (2) in his series of type 1 diabetic patients did not mention a single patient with either lipohypertrophy or lipoatrophy. Lypohypertrophy is a consequence of repeated insulin injections at the same sites and may complicate treatment leading to delayed insulin absorption. The low number of patients with lipohypertrophy in our series may result from a failure to recognize subtle changes amenable only to careful palpation, but still the prevalence of visible lesions should range from 15 to 50% according to previous studies (18, 19) . The low prevalence of cutaneous reactions to insulin therapy in our patients might be a result of regular education of our patients and their parents about adequate injection technique with a division of main injection areas in several zones (e.g., abdomen in six to nine zones).
Keratosis pilaris proved to be significantly more prevalent among our type 1 diabetic patients than in control subjects (11.7 vs. 1.5%; 2P Ͻ 0.01). This disorder showed, in a stepwise logistic regression analysis, a highly significant association with ichthyosiform skin changes. This is in line with findings of the Israeli group (3, 20) linking keratosis pilaris to a high BMI, dry skin, and atopic eczema. In our series, only one patient had atopic eczema, and, unfortunately, we did not calculate the BMI of our patients. The age of a majority of our type 1 diabetic patients with keratosis pilaris (21 of 27) was Ͼ10 years. There was no preponderance of adolescent girls in our patients with keratosis pilaris, as suggested in some studies (21) . It seems that skin xerosis plays a significant role in the development of pilar keratosis.
Frequencies of other dermatologic conditions, unrelated to diabetes, were not different between patients and control subjects (Table 2) . When, like with halo nevi, a condition was present only in type 1 diabetic patients, the numbers were too small to draw any conclusion. We have not observed many other skin disorders associated with diabetes, such as generalized thick skin, diabetic dermopathy, yellow hands, acanthosis nigricans, granuloma annulare, multiple skin tags, or ulcers. The most likely explanation is the relatively short duration of diabetes in our pediatric and adolescent patients with type 1 diabetes compared with previous cross-sectional studies (2, 3) .
Results of the cross-sectional study confirm that the most prevalent cutaneous manifestation in young patients with type 1 diabetes is dry skin. As suggested by Yosipovitch et al. (3) , keratosis pilaris is also a condition disproportionately represented in the type 1 diabetic population. Both conditions appear early in the course of the disease and do not correlate with its duration. In our study, the type 1 diabetic patient population was younger and had shorter diabetes duration than those described in previous studies, did not have retinopathy and neuropathy, and had a very low prevalence of nephropathy and hypertension. This may explain the rarity of other diabetesassociated cutaneous manifestations. In comparing mean disease duration in our population and the Israeli population (3) of type 1 diabetic patients (4.2 vs. 13 years), it may be supposed that many of the diabetes-related skin disorders begin to develop after the 5th year of diabetes (In 71% of our patients, the duration of diabetes was Ͻ5 years.)
A prospective arm of the study analyzing cutaneous manifestations in the same cohort of young patients after several years would offer additional data on the natural history of skin lesions in patients with type 1 diabetes in relation to the disease duration and microvascular complications. The frequency and type of cutaneous lesions justify the early inclusion of a dermatologist in the management of type 1 diabetic patients in order to recognize and treat the disorders and direct further research into prevention some of the lesions, especially in those with an underlying fibrosing process.
